Medicover AB Series B (0RPS) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Medicover AB Series B SEK 148, price SEK 256, upside -42.1%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medicover AB Series B for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services.
Show more
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services. Its Healthcare Services include outpatient and inpatient care; dental care, mental health care, orthopedics, preventive plans and sports, and wellness; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness; hospital care; and preventive care services. The company's Diagnostic Services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It serves corporate, individuals, and public sector clients. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
Stock analysis
Medicover AB Series B (0RPS) currently trades at kr 255.50, while our model-based Fair Value estimate is kr 148.03, 42.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 26.77 per share, and 0 of the 26 models we run sit above the kr 255.50 price.
Bear case: the Growth Earnings group reads lowest at kr 15.03, and 26 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: kr 103.61 (bear) to kr 192.45 (bull), the price of kr 255.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Industrials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Medicover AB Series B reported revenue of 2.4B SEK in FY2025 versus 1.4B SEK in FY2021, a compound +15.2%/yr. Reported net income was 79.0M SEK in FY2025, compounding −6.2%/yr from FY2021.
Key figures
Market cap 38.6B SEK (≈ $3.8B) · P/E ratio 3.6 · P/S ratio 0.12 · EPS (TTM) kr 0.5940 · Dividend yield 9.5% · Net margin 3.3% · Return on equity 13.9% · Return on assets (EBIT) 5.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −40% fair-value upside, at −42%, 0RPS screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (kr 2.60 to kr 48.18). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear kr 103.61Fair Value kr 148.03Bull kr 192.45
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.2979 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+15.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.4%
Start year 2020 (pandemic). Over 10 years: +19.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+4.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.5%
Dividend (yield on the price)9.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.5% vs 8.9%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 7%
2025 sits 370% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 3.4%/yr over ~9Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Health Care Providers & Services” was too small, so the broader sector is used.)Industrials · 5313 stocks
Beats the sector median on 7/10 measures
Overall it ranks above its sector peers.
Valuation
Quality Score59 · Above median
Fair Value upside−42.1% · Below median
Profitability
Return on equity (TTM)13.9% · Above median
Return on assets4.6% · Above median
Net margin (TTM)3.3% · Below median
Operating margin (TTM)7.5% · Above median
Growth and dividend
Revenue growth8.0% · Above median
Dividend yield (TTM)9.5% · Top 25%
Balance sheet
Debt / equity0.29× · Above median
Valuation Multiplesvs Industrials median · lower = cheaper
P/E (TTM)3.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)40· sector 37
PAST (return on equity)55· sector 29
HEALTH (low debt)86· sector 94
DIVIDEND (yield)100· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medicover AB Series B Fair Value". https://www.fairvalue-calculator.com/stock/0RPS
Frequently asked questions
Is Medicover AB Series B (0RPS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 148.03 versus a price of kr 255.50, about −42% upside (overvalued).
What is the fair value of 0RPS?
Our model-based fair value for Medicover AB Series B is kr 148.03 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 255.50.
What is the quality score of 0RPS?
Medicover AB Series B has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicover AB Series B (0RPS)?
Our model-based price target is the fair value of kr 148.03 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario kr 103.61, optimistic scenario kr 192.45. It is a calculation from audited fundamentals, not an analyst target.
What is the Medicover AB Series B stock forecast for 2026?
Our models put fair value at kr 148.03, about −42% upside versus a price of kr 255.50 (overvalued). Cautious scenario kr 103.61, optimistic scenario kr 192.45. The calculation is refreshed regularly with new filings.
What is the revenue of Medicover AB Series B (0RPS)?
Medicover AB Series B reported trailing-twelve-month revenue of about 2.4B SEK (latest available figure, as of Sep 24, 2026).
Does Medicover AB Series B pay a dividend?
Medicover AB Series B currently shows a dividend yield of about 9.48% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Medicover AB Series B (0RPS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicover AB Series B it is kr 148.03 per share (as of Sep 24, 2026), against a price of kr 255.50. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Medicover AB Series B stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0RPS trades above its calculated fair value: price kr 255.50, fair value kr 148.03, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RPS?
No. The price is what the market pays today (kr 255.50); the fair value is what the company's own numbers justify (kr 148.03). For Medicover AB Series B the two are kr 107.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicover AB Series B worth?
The market values Medicover AB Series B at about 38.6B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 255.50; our models calculate a fair value of kr 148.03 per share.
What do the bullish and bearish scenarios say about 0RPS?
Our models span a range for Medicover AB Series B: cautious scenario kr 103.61, base kr 148.03, optimistic kr 192.45 per share (as of Sep 24, 2026, price kr 255.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0RPS?
Medicover AB Series B trades at a price-to-earnings ratio of 3.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 148.03 is built from several models across several years.
How solid is the balance sheet of Medicover AB Series B (0RPS)?
Balance-sheet figures for Medicover AB Series B (as of Sep 24, 2026): return on equity 13.9%, debt of 0.29 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 0RPS from its 52-week high?
Medicover AB Series B trades at kr 255.50, about 2% below its 52-week high of kr 260.50 and 42% above the low of kr 180.21 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 148.03 is for.
Which stocks are comparable to Medicover AB Series B?
From the same area (Industrials) we also value PINC, Contemporary Amperex Technology Co, Delta Electronics (Thailand) Public Company, Larsen & Toubro Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicover AB Series B stock attractive at the current price?
The data as of Sep 24, 2026: price kr 255.50, calculated fair value kr 148.03 (−42%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RPS calculated?
We run Medicover AB Series B through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 148.03, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Medicover AB Series B itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicover AB Series B (0RPS)?
The closing price on Oct 2, 2026 was kr 255.50. Our model-based fair value is kr 148.03, about −42% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicover AB Series B right now?
The price sits above even our optimistic bull case (kr 192.45). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 103.61 to kr 192.45) leaves room in how you read the outcome.
Where does the earnings growth of Medicover AB Series B (0RPS) come from?
Earnings per share at Medicover AB Series B grew +8.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.4 %, EBIT margin +0.0 %, tax rate +6.6 %, residual (interest, one-offs) −2.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Medicover AB Series B
How large is the market capitalisation of Medicover AB Series B (0RPS)?
The market capitalisation of Medicover AB Series B is 38.6B SEK (≈ $3.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medicover AB Series B (0RPS)?
The price-to-sales ratio of Medicover AB Series B is 0.12 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medicover AB Series B (0RPS)?
Earnings per share at Medicover AB Series B are kr 0.5940 (price ÷ EPS = P/E 3.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Medicover AB Series B (0RPS)?
The dividend yield of Medicover AB Series B is 9.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Medicover AB Series B (0RPS)?
The net margin of Medicover AB Series B is 3.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medicover AB Series B (0RPS)?
The return on equity (ROE) of Medicover AB Series B is 13.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medicover AB Series B (0RPS)?
On an EBIT basis the return on assets of Medicover AB Series B is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicover AB Series B (0RPS)?
The operating margin of Medicover AB Series B is 7.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medicover AB Series B (0RPS)?
Revenue at Medicover AB Series B is growing +8.0% versus a year earlier (3y avg +17.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medicover AB Series B (0RPS)?
Earnings per share at Medicover AB Series B are growing +9.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medicover AB Series B (0RPS) generate?
The free cash flow of Medicover AB Series B is 131M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medicover AB Series B (0RPS) carry?
The net debt of Medicover AB Series B is 1.8B SEK (fiscal year 2025, ≈ 13.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medicover AB Series B in the live analysis
One click puts Medicover AB Series B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
